4th annual Immunogenicity conference London, England, UK 12-13 June 2017

Description:
SMi is thrilled to present the return of its 4th annual Immunogenicity conference and exhibition, taking place in London on the 12th – 13th June 2017.

The immunogenicity market has seen considerable progression over recent years, with innovative developments apparent in predicting and controlling immunogenicity. However the industry is still subject to complex hurdles and challenges.

This year’s conference will provide attendees with a thorough understanding of the continued need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. Speakers will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for all delegates in attendance, Immunogenicity 2017 will identify and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.

Price:
Book by 31 March: GBP 1199
Book By 28 April: GBP 1299
Book By 31 May: GBP 1399
Standard: GBP 1499

Speakers: Regeneron, EpiVax Inc., Boehringer Ingelheim, ProImmune Ltd, UCB, Roche, Selecta Biosciences, Novartis, NIBSC, MHRA, EpiVax Inc, AbbVie, INSERM, Merck and many more